7th Nov 2007 07:57
Genus PLC07 November 2007 For Immediate Release 7 November 2007 Genus plc ("Genus" or "the Company") Publication of Prospectus Move to the Official List Genus plc (AIM: GNS), a world leading animal genetics company, is pleased toannounce that it has published its prospectus in connection with the proposedlisting of its entire issued ordinary share capital on the Official List of theUK Listing Authority and admission to trading on the London Stock Exchange'smarket for listed securities ("Admission"). It is expected that Admission will become effective and that dealings on theLondon Stock Exchange's main market will commence at 8.00 am on Monday 12November 2007. Trading in the Company's ordinary shares on AIM will becancelled simultaneously. The Company's stock code will continue to be LSE: GNS (GNS.L for Reuters and GNSLN for Bloomberg) and there will be 59,204,190 ordinary shares in issue onAdmission. Copies of the prospectus are available from the "Investors" section of theCompany's website at www.genusplc.com. The prospectus has also been submittedto the UKLA's Document Viewing Facility situated at: Financial ServicesAuthority, 25 The North Colonnade, Canary Wharf, London E14 5HS. For further information, please contact: Genus plc Tel: 01256 345970Richard Wood, Chief ExecutiveMartin Boden, Finance Director Landsbanki Securities (UK) Limited Tel: 020 7426 9000Nominated Adviser & Joint BrokerShaun Dobson Buchanan Communications Tel: 020 7466 5000Charles Ryland / Suzanne Brocks About Genus Genus creates and sells added value products for livestock farming and foodproducers by creating advances to animal breeding through biotechnology. Itsnon-Genetically Modified Organism (GMO) technology is applicable across alllivestock species but is only commercialised by Genus in the bovine and porcinefarming sectors. Genus' worldwide sales are made in seventy countries under the trade marks "ABS"(dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animalswith superior genetics to those animals currently in production. Customersproduce offspring with greater production efficiency, milk and meat output andquality and use these to supply the global dairy and meat supply chain. Genus' competitive edge has been created from the ownership and control ofproprietary lines of breeding animals, the biotechnology used to improve themand the Group's global production and distribution network. Headquartered in Basingstoke, England, Genus companies operate in 30 countrieson five continents, with research laboratories located in Madison, USA. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Genus